US2023256089A1PendingUtilityA1

Immunotherapy For The Treatment Of Allergic Disease

Assignee: GARCIA IBANEZ ROBERTOPriority: Aug 30, 2017Filed: Sep 15, 2022Published: Aug 17, 2023
Est. expiryAug 30, 2037(~11.1 yrs left)· nominal 20-yr term from priority
A61K 39/35A61P 37/08A61K 2039/54A61K 2039/542A61K 2039/545
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for the treatment of allergic disease include treating a subject in need thereof with a dosage of an allergen, wherein the allergen is administered to the subject’s oral vestibular space. In a preferred embodiment, the allergen is administered at night, thereby exploiting circadian rhythms in the subject’s immune response and enhancing the effectiveness of the treatment.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 16 . (canceled) 
     
     
         17 . A method for treating allergic disease in a human subject, the method comprising: 
 administering, at night, an allergen directly to a sublingual space.   
     
     
         18 . The method of  claim 17 , wherein the administering an allergen directly to a sublingual space comprises administering the allergen in multiple doses over a first period of time. 
     
     
         19 . The method of  claim 18 , wherein a concentration of the allergen increases over the first period of time. 
     
     
         20 . The method of  claim 17 , further comprising administering the allergen directly to an oral vestibular space. 
     
     
         21 . The method of  claim 20 , wherein the administering the allergen directly to an oral vestibular space comprises administering the allergen in multiple doses over a second period of time. 
     
     
         22 . The method of  claim 21 , wherein a concentration of the allergen remains constant over the second period of time.

Join the waitlist — get patent alerts

Track US2023256089A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.